The Prognostic Impact of HER2 Status and Survival Outcomes in Metastatic Triple Negative Breast Cancer
HER2-low expression was associated with significantly improved survival compared with HER2-negative status in metastatic TNBC. These findings highlight HER2 status as a potential prognostic factor, particularly relevant in settings with limited access to novel therapies such as immunotherapy or antibody-drug conjugates.
Authors
- Mesut Yılmaz (ORCID: https://orcid.org/0000-0001-8799-3452)
- DEVRİM ÇABUK
- Ece Baydar (ORCID: https://orcid.org/0000-0001-8527-936X)
- İlhan Hacıbekiroğlu (ORCID: https://orcid.org/0000-0002-0333-7405)
- Teoman Şakalar (ORCID: https://orcid.org/0000-0003-2749-9414)
- Rumeysa Çolak (ORCID: https://orcid.org/0000-0002-3867-0793)
- Alper Türkel (ORCID: https://orcid.org/0000-0001-5071-9679)
- Fatih Selçukbırıcık (ORCID: https://orcid.org/0000-0002-1273-1674)
- Eyyüp Çavdar (ORCID: https://orcid.org/0000-0001-5885-3047)
- Esma Sürmen-Gür (ORCID: https://orcid.org/0000-0001-7377-9682)
- Mehmet Ali Dogan (ORCID: https://orcid.org/0000-0003-3324-3028)
- Ahmet Öztürk (ORCID: https://orcid.org/0000-0002-9854-7586)
- Sinem Akbaş (ORCID: https://orcid.org/0000-0002-7197-211X)
Institutions
- Koç University (TR)
- Adıyaman University (TR)
- Ankara Onkoloji Eğitim ve Araştırma Hastanesi (TR)
- Sakarya Eğitim ve Araştırma Hastanesi (TR)
- Bakırköy Dr.Sadi Konuk Eğitim ve Araştırma Hastanesi (TR)
- Sağlık Bilimleri Üniversitesi (TR)
- Kahramanmaraş Sütçü İmam University (TR)
- Kocaeli Üniversitesi (TR)
- University of Health Sciences Antigua (AG)
Publication Details
- Journal
- In Vivo
- Published
- 2025-10-29
- DOI
- https://doi.org/10.21873/invivo.14160
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00